InvestorsHub Logo
Followers 4
Posts 1198
Boards Moderated 0
Alias Born 10/03/2015

Re: None

Saturday, 06/04/2022 11:03:54 PM

Saturday, June 04, 2022 11:03:54 PM

Post# of 304
phase II trial of the autologous anti-CD19 chimeric antigen receptor (CAR)
T-cell therapy brexucabtagene autoleucel (KTE-X19) in patients with heavily pretreated MCL
The median DOR was 46.7 months among patients with CR (46/71) and 2.2 months in patients with PR (16/71)
https://ascopubs.org/doi/pdf/10.1200/JCO.21.02370#.YptkxkBhQis.twitter
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DTIL News